The goal of fatty liver disease treatment is to reduce hepatic fat accumulation, prevent disease progression to liver fibrosis or cirrhosis, and lower the risk of cardiovascular disease. Currently, there are no approved specific medications for this condition, so treatment focuses on controlling metabolic abnormalities and improving liver metabolism. Physicians will tailor personalized treatment plans based on whether the patient has comorbidities such as diabetes, obesity, or dyslipidemia.
Therapeutic strategies require a combination of medical monitoring and lifestyle modifications, with regular follow-up on liver function and fat content changes. Severe cases may require invasive interventions, but the majority of patients are managed primarily through non-pharmacological interventions. Involvement of multidisciplinary medical teams (including nutritionists and exercise therapists) can significantly enhance treatment outcomes.
Current treatments include pharmacological therapies directly targeting liver fat and non-pharmacological strategies indirectly improving systemic metabolic abnormalities. Medications mainly address factors related to metabolic syndrome rather than directly dissolving hepatic fat. Non-drug therapies are fundamental, especially in early stages, effectively preventing disease progression.
The choice of treatment depends on the type of fatty liver: Alcoholic fatty liver disease requires priority alcohol cessation, while non-alcoholic fatty liver disease (NAFLD) focuses on addressing insulin resistance and metabolic issues. Patients with severe fibrosis may need liver biopsy to assess treatment efficacy, and medication choices should exclude contraindications related to liver metabolism abnormalities.
Currently, the number of drugs approved by the Food and Drug Administration (FDA) remains limited, but the following are considered potential options in clinical practice:
Experimental drugs include ACAT1 inhibitors and FXR receptor agonists, which can directly regulate hepatic lipid metabolism pathways. Clinical trials show that FXR agonist obeticholic acid can reduce liver fibrosis indices, but monitoring for side effects such as bile acid metabolism abnormalities is necessary.
Invasive treatments are currently reserved for extreme cases:
Alternative therapies should be carefully evaluated; herbal supplements such as milk thistle lack proven efficacy and may interact with medications. All invasive treatments require assessment of the patient’s overall metabolic status and surgical risks prior to proceeding.
A low-carbohydrate diet (<50% of caloric intake) effectively reduces liver fat. The Mediterranean diet, rich in Omega-3 fatty acids and fiber, has been proven to improve NAFLD indices. Avoid trans fats and refined sugars; it is recommended that 15-20% of daily calories come from high-quality proteins (such as fish and legumes).
Engaging in 150 minutes of moderate-intensity aerobic exercise per week (such as brisk walking or swimming) combined with resistance training can effectively reduce liver fat content. Studies indicate that exercise programs incorporating intermittent fasting can improve insulin sensitivity by over 20%. Exercise intensity should be adjusted based on liver function, and patients with severe cirrhosis should avoid excessive energy expenditure training.
Controlling body weight to a BMI <24 is a key strategy; weight loss of 7-10% has been shown to significantly improve hepatic fat accumulation. Diabetic patients should aim to keep HbA1c below 6.5%, and hyperlipidemic patients should reduce LDL cholesterol to <100 mg/dL. Alcohol abstinence is the first-line treatment for alcoholic fatty liver disease and requires complete alcohol avoidance.
Gene therapy and liver-targeted drugs are current research hotspots. Techniques such as delivering siRNA via nanoparticle carriers to inhibit hepatic fat synthesis pathways are in clinical trials. Mesenchymal stem cell transplantation aims to repair liver fibrosis, but long-term safety remains to be evaluated.
Artificial intelligence diagnostic systems can assess liver fat content in real-time, combined with wearable devices tracking metabolic indicators, potentially forming personalized treatment platforms in the future. Genotyping analysis can help predict treatment responses, such as patients with PPARG gene polymorphisms responding better to specific medications.
Seek immediate medical attention if experiencing unexplained fatigue, right upper abdominal distension or pain, or jaundice. Liver function tests showing AST/ALT ratio >2, or ultrasound indicating severe fatty liver (S2-S3 grade), should prompt referral to gastroenterology or hepatology specialists for further assessment. Patients with coexisting type 3 hyperlipidemia or metabolic syndrome should have liver ultrasound follow-up every 6 months.
If after 6-12 months of treatment, liver fat content has not improved or if portal hypertension symptoms (such as esophageal varices) develop, evaluation by a hepatologist is necessary. Regular monitoring of liver enzymes and renal function is required during medication therapy, especially for those on Vitamin E for more than 6 months, due to potential risks of fat-soluble vitamin metabolism abnormalities.
Alcohol consumption can exacerbate liver cell damage in fatty liver disease, so complete abstinence is recommended during treatment. Even in non-alcoholic fatty liver disease, reducing alcohol intake can lower the risk of hepatitis and cirrhosis. The World Gastroenterology Organisation recommends avoiding alcohol for at least 6 months and regularly monitoring liver function.
Which nutrients should be particularly monitored in dietary control?Prioritize a high-fiber, low-sugar, and low-fat diet. Omega-3 fatty acids (such as fish oil) can improve insulin resistance; Vitamin E may help repair liver cells but should be used under medical supervision. Avoid refined sugars and trans fats, such as in desserts and fried foods.
How should underweight patients treat fatty liver?Underweight individuals may have fatty liver due to metabolic abnormalities or insufficient muscle mass. Treatment should be individualized. Physicians may recommend increasing protein intake, resistance exercises to build muscle, and managing diabetes or metabolic syndrome, rather than solely focusing on weight loss.
Does a reduction in liver fat content after treatment mean recovery?While decreased fat content indicates improvement, fibrosis or inflammation may not be fully repaired. Continued follow-up with ultrasound or FibroScan, along with blood glucose and lipid assessments, is necessary to determine true recovery.
Are herbal medicines or supplements effective for fatty liver?Some herbs like silymarin may have antioxidant effects, but large-scale clinical trials confirming efficacy are lacking. Use should be disclosed to physicians, as some herbal medicines may interact with liver enzymes and worsen liver damage. Lifestyle modifications remain the primary recommendation.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
